Treatment of immune thrombocytopenia after allogeneic cord blood stem cell transplantation with rituximab: a case report

[1]  S. Vesely,et al.  Fatigue in adult patients with primary immune thrombocytopenia , 2011, European journal of haematology.

[2]  J. George,et al.  Definition, diagnosis and treatment of immune thrombocytopenic purpura , 2009, Haematologica.

[3]  F. Dentali,et al.  Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura , 2007, Annals of Internal Medicine.

[4]  Chen Yan,et al.  The Characteristics of Immunophenotype in Acute Lymphoblastic Leukemia and Its Clinical Significance , 2005 .

[5]  R. Mcmillan,et al.  The Effect of Antiplatelet Autoantibodies on Megakaryocytopoiesis , 2005, International journal of hematology.

[6]  V. Blanchette,et al.  Immune thrombocytopenic purpura. , 2002, The New England journal of medicine.

[7]  S. Amadori,et al.  Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. , 2001, Blood.

[8]  F. Frassoni,et al.  Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft‐versus‐host disease, donor type, cytomegalovirus infections and cell dose , 2001, British journal of haematology.

[9]  G. Yanik,et al.  Anti-CD20 Chimeric Monoclonal Antibody Treatment of Refractory Immune-Mediated Thrombocytopenia in a Patient with Chronic Graft-versus-Host Disease , 2000, Annals of Internal Medicine.

[10]  A. Jillella,et al.  Autoimmune thrombocytopenia following autologous hematopoietic cell transplantation: review of literature and treatment options , 2000, Bone Marrow Transplantation.